SG Americas Securities LLC Buys 17,577 Shares of MacroGenics, Inc. (NASDAQ:MGNX)

SG Americas Securities LLC grew its stake in MacroGenics, Inc. (NASDAQ:MGNX) by 104.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 34,399 shares of the biopharmaceutical company’s stock after acquiring an additional 17,577 shares during the period. SG Americas Securities LLC’s holdings in MacroGenics were worth $112,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. raised its position in MacroGenics by 64.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,064 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 4,707 shares during the last quarter. XML Financial LLC increased its stake in shares of MacroGenics by 31.6% in the 4th quarter. XML Financial LLC now owns 23,169 shares of the biopharmaceutical company’s stock valued at $75,000 after buying an additional 5,569 shares during the period. Stifel Financial Corp raised its position in shares of MacroGenics by 19.7% during the third quarter. Stifel Financial Corp now owns 39,888 shares of the biopharmaceutical company’s stock worth $131,000 after acquiring an additional 6,578 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of MacroGenics during the third quarter valued at $37,000. Finally, Sanders Morris Harris LLC bought a new position in MacroGenics in the fourth quarter valued at about $40,000. 96.89% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have weighed in on MGNX shares. StockNews.com raised MacroGenics from a “sell” rating to a “buy” rating in a report on Sunday, November 10th. HC Wainwright reaffirmed a “neutral” rating and issued a $4.00 target price on shares of MacroGenics in a research note on Wednesday, November 6th. Finally, JMP Securities lowered shares of MacroGenics from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 7th. Eight investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, MacroGenics presently has a consensus rating of “Hold” and a consensus price target of $7.63.

MacroGenics Price Performance

Shares of NASDAQ:MGNX opened at $2.40 on Thursday. The company has a market capitalization of $150.62 million, a price-to-earnings ratio of -1.52 and a beta of 2.02. The firm’s 50 day simple moving average is $3.14 and its 200 day simple moving average is $3.45. MacroGenics, Inc. has a fifty-two week low of $2.34 and a fifty-two week high of $21.88.

MacroGenics Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.